【开放获取】中国荨麻疹诊疗指南（2022版）

doi:10.35541/cjd.20220609

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (12): 1041-1049.doi: 10.35541/cjd.20220609

【开放获取】中国荨麻疹诊疗指南（2022版）

中华医学会皮肤性病学分会荨麻疹研究中心

中华医学会皮肤性病学分会荨麻疹研究中心

收稿日期:2022-08-30 修回日期:2022-10-14 发布日期:2022-12-05
通讯作者: 徐金华；郝飞 E-mail:xjhhsyy@163.com; haofei62@126.com
基金资助:
上海市级医院皮肤科临床能力促进与提升专科联盟（SHDC22022302）

Guideline for diagnosis and treatment of urticaria in China （2022）

Centre for Urticaria Research, Chinese Society of Dermatology

Centre for Urticaria Research, Chinese Society of Dermatology

Received:2022-08-30 Revised:2022-10-14 Published:2022-12-05
Contact: Xu Jinhua; Hao Fei E-mail:xjhhsyy@163.com; haofei62@126.com
Supported by:
Clinical Research Plan of SHDC（SHDC22022302）

摘要/Abstract

摘要： 【摘要】荨麻疹是一种以风团和瘙痒为主要表现的常见皮肤病，部分病例存在病情迁延反复、临床疗效不佳等特点。本指南以2018版中国荨麻疹诊疗指南为基础，结合近年来国内外荨麻疹的最新研究进展，经中华医学会皮肤性病学分会荨麻疹研究中心数十位专家共同讨论后制定而成，适用于中国成人及儿童荨麻疹患者。除对荨麻疹的定义、发病机制等内容进行补充和更新外，还采用问答形式对荨麻疹分类、诊断及治疗等临床实践中重点关注的内容进行细致说明，以期为荨麻疹的诊疗提供更为全面、科学和权威的参考依据。

关键词: 荨麻疹, 诊断, 治疗, 指南

Abstract: 【Abstract】 Urticaria is a common skin disease characterized by wheals and pruritus, and some refractory cases showed prolonged duration and poor response to treatment. This guideline is a refinement of the previous version of the guideline for diagnosis and treatment of urticaria in China （2018）, and is developed by dozens of experts from Centre for Urticaria Research, Chinese Society of Dermatology after joint discussions on the basis of recent clinical and investigational advances in urticaria in China and other countries. This guideline is suitable for both Chinese adults and children with urticaria. In addition to supplementing and updating the definition and pathogenesis of urticaria, the guideline also provides detailed explanations about key concerns in clinical practicethe, such as the classification, diagnosis and treatment of urticaria, in the form of questions and answers. The guideline may provide a more comprehensive, scientific and authoritative reference for diagnosis and management of urticaria.

Key words: Urticaria, Diagnosis, Therapy, Guideline

中华医学会皮肤性病学分会荨麻疹研究中心. 【开放获取】中国荨麻疹诊疗指南（2022版）[J]. 中华皮肤科杂志, 2022,55(12):1041-1049. doi:10.35541/cjd.20220609

Centre for Urticaria Research, Chinese Society of Dermatology. Guideline for diagnosis and treatment of urticaria in China （2022）[J]. Chinese Journal of Dermatology, 2022, 55(12): 1041-1049.doi:10.35541/cjd.20220609

参考文献 44

［1］	中华医学会皮肤性病学分会免疫学组. 中国荨麻疹诊疗指南（2014版）［J］. 中华皮肤科杂志, 2014,47（7）:514⁃516.
［2］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［3］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［4］	赵作涛. 慢性荨麻疹诊治：现状与展望［J］. 中华皮肤科杂志, 2021,54（12）:1105⁃1109. doi: 10.35541/cjd.20210744.
［5］	Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study［J］. Chin Med J （Engl）, 2022,135（11）:1369⁃1375. doi: 10.1097/CM9.0000000000002172.
［6］	Zhang L, Qiu L, Wu J, et al. GWAS of chronic spontaneous urticaria reveals genetic overlap with autoimmune diseases, not atopic diseases［J］. J Invest Dermatol, 2022. doi: 10.1016/j.jid.2022.07.012.
［7］	Maurer M, Taube C, Schröder N, et al. Mast cells drive IgE⁃mediated disease but might be bystanders in many other inflammatory and neoplastic conditions［J］. J Allergy Clin Immunol, 2019,144（4S）:S19⁃S30. doi: 10.1016/j.jaci.2019.07.017.
［8］	Kabashima K, Nakashima C, Nonomura Y, et al. Biomarkers for evaluation of mast cell and basophil activation［J］. Immunol Rev, 2018,282（1）:114⁃120. doi: 10.1111/imr.12639.
［9］	Wedi B, Traidl S. Anti⁃IgE for the treatment of chronic urticaria［J］. Immunotargets Ther, 2021,10:27⁃45. doi: 10.2147/ITT.S26 1416.
［10］	Belmesk L, Muntyanu A, Cantin E, et al. Prominent role of type 2 immunity in skin diseases: beyond atopic dermatitis［J］. J Cutan Med Surg, 2022,26（1）:33⁃49. doi: 10.1177/1203475421 1027858.
［11］	朱奕锜, 唐慧, 王朵勤, 等. 维生素D与慢性荨麻疹的研究进展［J］. 国际皮肤性病学杂志, 2017,43（4）:223⁃226. doi: 10. 3760/cma.j.issn.1673⁃4173.2017.04.010.
［12］	Wang D, Tang H, Shen Y, et al. Activation of the blood coagulation system in patients with chronic spontaneous urticaria［J］. Clin Lab, 2015,61（9）:1283⁃1288. doi: 10.7754/clin.lab.2015.150226.
［13］	Kanani A, Betschel SD, Warrington R. Urticaria and angioedema［J］. Allergy Asthma Clin Immunol, 2018,14（Suppl 2）:59. doi: 10.1186/s13223⁃018⁃0288⁃z.
［14］	Davis M, van der Hilst J. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1162⁃1170. doi: 10.1016/j.jaip.2018. 05.006.
［15］	康玉英, 何肖, 刘勇, 等. 急性荨麻疹住院患者185例回顾分析［J］. 中华皮肤科杂志, 2018,51（3）:224⁃227. doi: 10.3760/cma.j.issn.0412⁃4030.2018.03.016.
［16］	Guarneri C, Ceccarelli M, Rinaldi L, et al. Helicobacter pylori and skin disorders: a comprehensive review of the available literature［J］. Eur Rev Med Pharmacol Sci, 2020,24（23）:12267⁃12287. doi: 10.26355/eurrev_202012_24019.
［17］	Zhang L, Qiu L, Wu J, et al. IgE and IgG anti⁃thyroid autoantibodies in Chinese patients with chronic spontaneous urticaria and a literature review［J］. Allergy Asthma Immunol Res, 2022,14（1）:131⁃142. doi: 10.4168/aair.2022.14.1.131.
［18］	中国医师协会变态反应医师分会, 福棠儿童医学发展研究中心, 北京医师协会变态反应专科医师分会. 过敏原特异性IgE检测结果临床解读中国专家共识［J］.中华预防医学杂志,2022,56（6）:707⁃725. doi: 10.3760/cma.j.cn112150⁃20220320⁃00263.
［19］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［20］	陈玉迪, 刘擘, 宋晓婷, 等. 临界温度阈值检测在冷接触性荨麻疹中的临床应用［J］. 中华皮肤科杂志, 2020,53（5）:352⁃355. doi: 10.35541/cjd.20190840.
［21］	中华医学会皮肤性病学分会荨麻疹研究中心. 慢性荨麻疹患者宣教指南［J］. 中华皮肤科杂志, 2022,e20220305. doi:10. 35541/cjd.20220305.
［22］	Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study［J］. Allergy, 2014,69（3）:359⁃364. doi: 10.1111/all.12338.
［23］	Choi GS, Nam YH, Park CS, et al. Anxiety, depression, and stress in Korean patients with chronic urticaria［J］. Korean J Intern Med, 2020,35（6）:1507⁃1516. doi: 10.3904/kjim.2019.320.
［24］	Cataldi M, Maurer M, Taglialatela M, et al. Cardiac safety of second⁃generation H（1） ⁃antihistamines when updosed in chronic spontaneous urticaria［J］. Clin Exp Allergy, 2019,49（12）:1615⁃1623. doi: 10.1111/cea.13500.
［25］	Zhang L, Wu J, Qi Y, et al. Long⁃term combinations and updosing of second⁃generation H1⁃antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: a multicenter real⁃life pilot study［J］. J Allergy Clin Immunol Pract, 2020,8（5）:1733⁃1736.e11. doi: 10.1016/j.jaip.2019.12. 006.
［26］	Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
［27］	Kocatürk E, Deza G, Kızıltaç K, et al. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients［J］. Int Arch Allergy Immunol, 2018,177（4）:360⁃364. doi: 10. 1159/000491530.
［28］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017.
［29］	Kessel A, Toubi E. Cyclosporine⁃a in severe chronic urticaria: the option for long⁃term therapy［J］. Allergy, 2010,65（11）:1478⁃1482. doi: 10.1111/j.1398⁃9995.2010.02419.x.
［30］	Liu L, Zhao H, Sun X, et al. Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta⁃analysis［J］. BMC Complement Altern Med, 2018,18（1）:243. doi: 10.1186/s12906⁃018⁃2305⁃7.
［31］	Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2019,381（14）:1321⁃1332. doi: 10.1056/NEJMoa1900408.
［32］	Errichetti E, Stinco G. Recalcitrant chronic urticaria treated with dupilumab: report of two instances refractory to H1⁃antihistamines, omalizumab and cyclosporine and brief literature review［J］. Dermatol Ther, 2021,34（2）:e14821. doi: 10.1111/dth.14821.
［33］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［34］	Altrichter S, Staubach P, Pasha M, et al. An open⁃label, proof⁃of⁃concept study of lirentelimab for antihistamine⁃resistant chronic spontaneous and inducible urticaria［J］. J Allergy Clin Immunol, 2022,149（5）:1683⁃1690.e7. doi: 10.1016/j.jaci.2021.12.772.
［35］	Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H（1） antihistamine⁃refractory chronic spontaneous urticaria: a randomized phase 2 trial［J］. Nat Med, 2021,27（11）:1961⁃1969. doi: 10. 1038/s41591⁃021⁃01537⁃w.
［36］	Kaul M, End P, Cabanski M, et al. Remibrutinib （LOU064）: a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial［J］. Clin Transl Sci, 2021,14（5）:1756⁃1768. doi: 10.1111/cts.13005.
［37］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10. 1111/bjd.14543.
［38］	Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674.
［39］	Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
［40］	Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry （EXPECT）: the safety of omalizumab use during pregnancy［J］. J Allergy Clin Immunol, 2015,135（2）:407⁃412. doi: 10.1016/j.jaci.2014.08.025.
［41］	Cornillier H, Giraudeau B, Munck S, et al. Chronic spontaneous urticaria in children ⁃ a systematic review on interventions and comorbidities［J］. Pediatr Allergy Immunol, 2018,29（3）:303⁃310. doi: 10.1111/pai.12870.
［42］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686.
［43］	Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real⁃life data from a multicenter observational study focusing on elderly patients［J］. Dermatol Ther, 2021,34（2）:e14841. doi: 10.1111/dth.14841.
［44］	温禾, 姚煦. 抗组胺药在特殊人群中的应用［J］. 中华皮肤科杂志, 2016,49（9）:669⁃671. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.09.022.

[1]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128.
[2]	任芬芬王鹏张景展康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 0(3): 20220140-e20220140.
[3]	杨骥徐欣植李明. 皮肌炎的早期诊断和内脏损伤早期识别[J]. 中华皮肤科杂志, 2023, 56(2): 161-164.
[4]	贾元源毛秋雨杨婧怡闵玮. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察[J]. 中华皮肤科杂志, 2023, 56(2): 125-129.
[5]	佟馨吴剑张立明高兴华连石张海萍朱威郭在培黎静宜李萌萌何黎农祥普雄明于世荣陈洪铎肖汀. 食物特异性IgG抗体与慢性自发性荨麻疹表型的相关性研究[J]. 中华皮肤科杂志, 2023, 56(2): 130-135.
[6]	中华医学会皮肤性病学分会中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病学分会中国医药教育协会皮肤病专业委员会. 老年带状疱疹诊疗专家共识[J]. 中华皮肤科杂志, 2023, 56(2): 97-104.
[7]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210803-e20210803.
[8]	李婷婷康晓静. 肠道菌群与黑素瘤免疫检查点抑制剂治疗的研究进展[J]. 中华皮肤科杂志, 2023, 56(2): 177-180.
[9]	孙静徐英男林彤薛劲松. 重度玫瑰痤疮眼型28例眼部损害临床治疗结局分析[J]. 中华皮肤科杂志, 2023, 56(2): 142-145.
[10]	于淼宋晓婷刘擘廖双璐栾婷婷赵作涛. 慢性自发性荨麻疹患者自体血清皮肤试验的免疫学机制及与临床特征和预后的关系[J]. 中华皮肤科杂志, 2023, 56(2): 184-187.
[11]	赵莹张晓艳陈璐苏玉华丁瑜洁冷红季江. 奥马珠单抗治疗难治性慢性自发性荨麻疹患者的疗效预测因子探索[J]. 中华皮肤科杂志, 2023, 56(1): 22-28.
[12]	杜方智张栩王千秋. 猴痘的临床表现与诊疗随访[J]. 中华皮肤科杂志, 2023, 56(1): 76-81.
[13]	中华医学会皮肤性病学分会玫瑰痤疮研究中心中国医师协会皮肤科医师分会玫瑰痤疮专业组. A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识[J]. 中华皮肤科杂志, 2023, 56(1): 16-21.
[14]	李巍李政. 【开放获取】典型与非典型表现的特应性皮炎[J]. 中华皮肤科杂志, 2023, 56(1): 1-4.
[15]	鲁楠谭兴友刘香牛李莉姚树兰. 微RNA单核苷酸多态性与慢性自发性荨麻疹发病风险的关联分析[J]. 中华皮肤科杂志, 2022, 55(9): 806-809.

【开放获取】中国荨麻疹诊疗指南（2022版）

Guideline for diagnosis and treatment of urticaria in China （2022）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

Metrics

本文评价

推荐阅读 10